Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760279 | 0.92 | MEN1 (0.44) | SLC2A1SIGMAR1DRD2HTR2AMEN1 | |
| SCHEMBL1921739 | 0.79 | L3MBTL1 (0.43) | SIGMAR1MEN1KMT2AKCNH2ALDH1A1 | |
| SCHEMBL2186819 | 0.78 | POLB (0.51) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL27825224 | 0.76 | PIK3CD (0.47) | DRD2ALDH1A1KDM4E | |
| SCHEMBL4515666 | 0.76 | ALDH1A1 (0.62) | SIGMAR1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7828734 | 0.75 | SMN1; SMN2 (0.55) | SIGMAR1HTR2AMEN1KMT2ACA1 | |
| SCHEMBL16825019 | 0.75 | L3MBTL3 (0.59) | KCNH2 | |
| SCHEMBL10086564 | 0.74 | KCNA5 (0.56) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL28373339 | 0.73 | LMNA (0.61) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL969710 | 0.73 | HPGD (0.52) | MEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | SLC2A1 3509/4885SIGMAR1 2498/4885DRD2 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.